ZA202100703B - Compositions and methods for treating inflammasome related diseases or conditions - Google Patents

Compositions and methods for treating inflammasome related diseases or conditions

Info

Publication number
ZA202100703B
ZA202100703B ZA2021/00703A ZA202100703A ZA202100703B ZA 202100703 B ZA202100703 B ZA 202100703B ZA 2021/00703 A ZA2021/00703 A ZA 2021/00703A ZA 202100703 A ZA202100703 A ZA 202100703A ZA 202100703 B ZA202100703 B ZA 202100703B
Authority
ZA
South Africa
Prior art keywords
compositions
conditions
methods
related diseases
inflammasome related
Prior art date
Application number
ZA2021/00703A
Other languages
English (en)
Inventor
W Keane Robert
Dalton Dietrich W
Pablo De Rivero Vaccari Juan
M Bramlett Helen
Brambilla Roberta
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of ZA202100703B publication Critical patent/ZA202100703B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ZA2021/00703A 2018-07-03 2021-02-01 Compositions and methods for treating inflammasome related diseases or conditions ZA202100703B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
PCT/US2019/040635 WO2020010273A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions

Publications (1)

Publication Number Publication Date
ZA202100703B true ZA202100703B (en) 2022-08-31

Family

ID=78823964

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2021/00703A ZA202100703B (en) 2018-07-03 2021-02-01 Compositions and methods for treating inflammasome related diseases or conditions
ZA2022/01437A ZA202201437B (en) 2018-07-03 2022-01-31 Compositions and methods for treating inflammasome related diseases or conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2022/01437A ZA202201437B (en) 2018-07-03 2022-01-31 Compositions and methods for treating inflammasome related diseases or conditions

Country Status (16)

Country Link
US (1) US12570735B2 (enExample)
EP (1) EP3818081A4 (enExample)
JP (2) JP7824030B2 (enExample)
KR (1) KR20210071944A (enExample)
CN (1) CN113316588B (enExample)
AU (1) AU2019297515A1 (enExample)
BR (1) BR112020026798A2 (enExample)
CA (1) CA3105129A1 (enExample)
CL (1) CL2020003447A1 (enExample)
CO (1) CO2021001172A2 (enExample)
IL (1) IL279851A (enExample)
MX (1) MX2021000142A (enExample)
PH (1) PH12020552286A1 (enExample)
SG (1) SG11202013176VA (enExample)
WO (1) WO2020010273A1 (enExample)
ZA (2) ZA202100703B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240060995A1 (en) * 2012-02-06 2024-02-22 University Of Miami Innate immune proteins as biomarkers for traumatic brain injury in adult and pediatric patients
JP2020503345A (ja) 2016-12-29 2020-01-30 ユニバーシティ オブ マイアミ 肺におけるインフラマソーム活性及び炎症をモジュレートする方法
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
MX2021000142A (es) 2018-07-03 2021-05-12 Univ Miami Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas.
EP4142705A4 (en) * 2020-04-27 2024-07-03 University of Miami Compositions and methods for treating inflammasome related diseases or conditions
TW202334202A (zh) * 2021-11-16 2023-09-01 瑞士商Ａｃ免疫有限公司 用於治療和診斷的新分子
JP2025530202A (ja) * 2022-09-09 2025-09-11 ユニバーシティー オブ マイアミ 神経疾患を治療するためのインフラマソーム抗体組成物及び方法
WO2024114906A1 (en) * 2022-11-30 2024-06-06 Mabylon Ag Antibodies against apoptosis-associated speck-like protein containing a card (asc) and uses thereof
WO2026042013A1 (en) * 2024-08-19 2026-02-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Mitochondrial therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763849B1 (fr) 1997-05-28 2000-09-15 Rhone Poulenc Rorer Sa Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2005243193B2 (en) 2004-04-29 2011-01-27 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein VI and methods of producing these antibodies
JP4496214B2 (ja) * 2004-05-17 2010-07-07 電気化学工業株式会社 ポリ塩化ビニル繊維及びその製造方法並びに人工毛髪
AU2005306997B2 (en) 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2623565A1 (en) 2005-09-28 2007-04-05 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2475380A1 (en) 2009-09-11 2012-07-18 Protaffin Biotechnologie AG Composition for treatment of cxcl8-mediated lung inflammation
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
IT1406201B1 (it) 2010-12-10 2014-02-14 Univ Degli Studi Trieste Biomarcatori per la diagnosi della sclerosi multipla
WO2012123299A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Asc as marker for chronic obstructive pulmonary disease (copd)
WO2013049278A1 (en) 2011-09-30 2013-04-04 Novartis Ag USE OF IL-1 ß BINDING ANTIBODIES
CA2863417C (en) 2012-02-06 2020-07-28 University Of Miami Innate immune proteins as biomarkers for cns injury
TWI480044B (zh) 2012-03-16 2015-04-11 Taichung Veterans General Hospital A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
CN105209643A (zh) 2013-05-17 2015-12-30 豪夫迈·罗氏有限公司 用于诊断和治疗炎性肠病的方法
JP6359013B2 (ja) 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 １，５−ｄ−アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬
EP4491180A1 (en) 2014-01-10 2025-01-15 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3183582B1 (en) 2014-08-18 2020-02-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
WO2016059571A1 (en) 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US20160263183A1 (en) 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
CN114181281A (zh) 2015-05-12 2022-03-15 加利福尼亚大学董事会 用于炎症和纤维化的肽治疗
CN108349867B (zh) 2015-08-17 2021-03-09 安成生物科技股份有限公司 用于抑制asc的表达、nlrp3的表达和/或nlrp3炎性复合体的形成的双醋瑞因或其类似物
KR101948048B1 (ko) * 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 톡소포자충 ｇｒａ７ 항원 유래 재조합 단백질을 유효성분으로 포함하는 결핵 예방 또는 치료용 약학 조성물
JP2020503345A (ja) 2016-12-29 2020-01-30 ユニバーシティ オブ マイアミ 肺におけるインフラマソーム活性及び炎症をモジュレートする方法
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
US10755739B1 (en) 2016-12-30 2020-08-25 John Fristrom Remote railway crossing programmable device and methods thereof
AU2018336897A1 (en) 2017-09-20 2020-04-30 University Of Miami Method for detecting inflammasome proteins as biomarkers of neurological disorders
MX2021000142A (es) 2018-07-03 2021-05-12 Univ Miami Composiciones y metodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas.

Also Published As

Publication number Publication date
EP3818081A4 (en) 2022-06-22
EP3818081A1 (en) 2021-05-12
JP7824030B2 (ja) 2026-03-04
ZA202201437B (en) 2024-05-30
WO2020010273A1 (en) 2020-01-09
CL2020003447A1 (es) 2021-07-30
US12570735B2 (en) 2026-03-10
SG11202013176VA (en) 2021-01-28
PH12020552286A1 (en) 2021-06-21
JP2021528092A (ja) 2021-10-21
BR112020026798A2 (pt) 2021-03-30
CO2021001172A2 (es) 2021-07-09
US20210284723A1 (en) 2021-09-16
AU2019297515A1 (en) 2021-02-25
CN113316588B (zh) 2025-02-28
KR20210071944A (ko) 2021-06-16
JP2025067915A (ja) 2025-04-24
IL279851A (en) 2021-03-01
JP7850296B2 (ja) 2026-04-22
CN113316588A (zh) 2021-08-27
MX2021000142A (es) 2021-05-12
CA3105129A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
IL279851A (en) Preparations and methods for treating diseases or conditions related to inflammasome
IL273959A (en) Methods and preparations for the treatment of rare diseases
IL274702A (en) Compounds and Methods for Neurological Diseases
AU2018297285A1 (en) Compositions and methods for treating or preventing endocrine FGF-linked diseases
EP3687524A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OPHTHALMIC DISORDERS
HUE073261T2 (hu) Készítmények fehérje-aggregációs betegségek kezelésére és/vagy megelõzésére
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL285886A (en) Preparations and methods for the treatment of laminopathy
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
IL275767A (en) Compositions and methods for treating metabolic diseases
IL272937A (en) Preparations and methods for the treatment of diseases involving fibrosis
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
EP3768095A4 (en) Compositions and methods for treating diarrheal diseases
EP3265103A4 (en) Compositions and methods for treating ocular diseases
IL261779A (en) Preparations for the treatment and prevention of hoof and claw disease
EP3672583A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
EP3496696A4 (en) COMPOUNDS AND METHODS FOR TREATING THE DISEASE.
EP3310338A4 (en) Compositions and methods for treating inflammatory disease or conditions
IL280262A (en) Compositions and methods for treating cancer
HK40053279A (en) Compositions and methods for treating nrp2-associated diseases
HK40021297A (en) Compositions and methods for treating or preventing gut permeability-related disorders
AU2018900992A0 (en) Compositions and methods for treating respiratory diseases